Men currently prescribed finasteride, a medication used to treat male pattern hair loss and benign prostatic hyperplasia (BPH), are being urged to stay vigilant for possible psychiatric and sexual side effects. The Medicines and Healthcare products Regulatory Agency (MHRA) has issued updated guidance, emphasising the importance of monitoring for these adverse reactions.
The advice highlights a range of potential side effects, including psychiatric symptoms such as depression, anxiety, and in rare cases, suicidal thoughts. Sexual side effects, which can persist even after stopping the medication, include erectile dysfunction, decreased libido, and ejaculation disorders. Patients experiencing any new or worsening symptoms are strongly advised to consult their doctor promptly.
Finasteride works by inhibiting the enzyme 5-alpha-reductase, which is involved in the metabolism of testosterone. While effective for its intended uses, the drug's impact on hormone levels is believed to contribute to the reported side effects. The MHRA's updated guidance aims to ensure both patients and healthcare professionals are fully aware of these risks, promoting earlier detection and management.
Healthcare professionals have been instructed to discuss these potential side effects with their patients before prescribing finasteride and to counsel them on what symptoms to look out for during treatment. This proactive approach is intended to empower patients to recognise and report any concerning changes in their mental health or sexual function, leading to timely intervention.
The decision to issue this updated advice follows ongoing monitoring of safety data and reports of adverse reactions from patients. While these side effects are not experienced by everyone, the MHRA underscores the importance of awareness to ensure patient safety and appropriate medical care. Patients should not stop taking their medication without first speaking to their doctor.